FindTrial
Sign In

Reactivity of immunohistochemical Ki67 and Her2neu markers in bladder cancer

Immunohistochemical expression of Ki67 and Her2neu in urothelial tumors.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/03/050573
Enrollment
50
Registered
2023-03-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C679- Malignant neoplasm of bladder, unspecified

Interventions

Intervention1: NIL: NIL

Sponsors

BPS GMC Khanpur Kalan, Sonepat.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All histopathologically proven cases of urothelial tumors in urinary bladder.

Exclusion criteria

Exclusion criteria: 1. Blocks cannot be retrieved. 2. Patients with history of chemotherapy and radiotherapy.

Design outcomes

Primary

MeasureTime frame
To study the Immunohistochemical expression of Ki67 and Her2/neu in urothelial tumors.Timepoint: 6 months—

Secondary

MeasureTime frame
1. To evaluate histomorphological spectrum of various urothelial tumors. 2. To estimate the expression of Ki67 and Her2/neu in urothelial tumors. 3. To correlate Ki67 and Her2/neu expression with grading of urothelial tumors.Timepoint: 6 months—

Countries

India

Contacts

Public ContactDr Niketa

BPS GMC (W), Khanpur Kalan, Sonepat

drdeepti.75@gmail.com8222007666

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026